Finite-Game Biotech Competition

Finite-game biotech competition is [[DavidWeng|大卫翁]]’s frame in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位 for an industry mood shift from open-ended platform breakthrough to more bounded competition inside existing drug categories, assets, and transaction structures. The episode contrasts a prior “infinite game” feeling around PD-1, mRNA, and CAR-T with a 2024-2025 market where companies fight over data increments, pricing, BD terms, and engineering combinations.

The concept is not pessimism alone. It explains why [[ADCEngineeringOptimization|ADC engineering]], [[PD1VEGFBispecific|PD-1/VEGF]], [[TCellEngagers|TCEs]], [[GLP1Agonists|GLP-1s]], and [[DualPayloadADC|dual-payload ADCs]] can still matter: mature markets reward better tradeoffs, not only entirely new platforms.

Key Claims

• Mature therapeutic platforms can still produce valuable products through differentiation and combination.
• Competition shifts from “does the platform work?” to “who gets enough clinical, manufacturing, cost, and commercial advantage?”
• BD and capital structure become part of the innovation system when technical novelty is incremental.
• The frame helps keep enthusiasm and disappointment in the same analysis rather than swinging between boom and winter.

Connections

• PD-1 Market Saturation, ADC Engineering Optimization, Dual-Payload ADC, and T-Cell Engagers - mature or recombined technical areas.
• Biotech License-Out Arbitrage, Reverse NewCo Biotech Model, and China Biotech Asset Repricing - transaction and asset-market expressions.
• GLP-1 Agonists and China Biotech Globalization - commercial competition examples.
• Investment Risk Management - discipline around interpreting finite-game opportunities.